Back to top
more

CRISPR Therapeutics (CRSP)

(Real Time Quote from BATS)

$60.03 USD

60.03
199,177

-1.94 (-3.13%)

Updated Nov 4, 2025 09:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy17.80%
3Hold9.42%
4Sell5.10%
5Strong Sell2.04%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (95 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.

Zacks Equity Research

What's in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.

Zacks Equity Research

Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag

by Zacks Equity Research

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.

Sweta Killa headshot

Biotech ETFs Jump on Roche-Spark Deal

by Sweta Killa

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

Zacks Equity Research

CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

by Zacks Equity Research

CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.

Zacks Equity Research

Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales

by Zacks Equity Research

Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.

Zacks Equity Research

Is a Beat in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

Zacks Equity Research

Vertex Terminates COO Ian Smith on Code of Conduct Violation

by Zacks Equity Research

Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.

Zacks Equity Research

Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

by Zacks Equity Research

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

Zacks Equity Research

Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

by Zacks Equity Research

Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.

Zacks Equity Research

Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3

by Zacks Equity Research

Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.

Zacks Equity Research

Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (CRSP) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

CRISPR THERAPTC (CRSP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -44.59% and -83.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.

Zacks Equity Research

CRISPR THERAPTC (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

CRISPR THERAPTC (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in the Cards for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.

Zacks Equity Research

What Lies in Store for Ligand (LGND) This Earnings Season?

by Zacks Equity Research

Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.

Zacks Equity Research

Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.

Zacks Equity Research

Endo (ENDP) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are expected to focus on the Xiaflex performance and pipeline updates when Endo (ENDP) reports third-quarter results.

Zacks Equity Research

Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?

by Zacks Equity Research

Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.

Zacks Equity Research

ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.

Zacks Equity Research

What's in the Cards for Nektar (NKTR) This Earnings Season?

by Zacks Equity Research

Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.

Zacks Equity Research

5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings

by Zacks Equity Research

There are still a number of drug/biotech companies poised to surpass third-quarter estimates.